呵呵，用自创消息打压_老虎社区_美港股上老虎 - 老虎社区

呵呵，用自创消息打压股价吸筹，这个大摩也是不要脸的

【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":449798527656512,"tweetId":"449798527656512","gmtCreate":1750840881943,"gmtModify":1750840967298,"author":{"id":3495021804105148,"idStr":"3495021804105148","authorId":3495021804105148,"authorIdStr":"3495021804105148","name":"Maskey","avatar":"https://static.tigerbbs.com/7c67f92659fef0104dfcb1362aad3923","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.15","exceedPercentage":"93.15%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>呵呵，用自创消息打压股价吸筹，这个大摩也是不要脸的</body></html>","htmlText":"<html><head></head><body>呵呵，用自创消息打压股价吸筹，这个大摩也是不要脸的</body></html>","text":"呵呵，用自创消息打压股价吸筹，这个大摩也是不要脸的","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/449798527656512","repostId":2546804291,"repostType":2,"repost":{"id":"2546804291","kind":"live","pubTimestamp":1750838919,"share":"https://www.laohu8.com/m/news/2546804291?lang=&edition=full","pubTime":"2025-06-25 16:08","market":"us","language":"zh","title":"【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23","url":"https://stock-news.laohu8.com/highlight/detail?id=2546804291","media":"智通财经","summary":"【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23日，礼来(LLY.US)在芝加哥举行的美国糖尿病协会(ADA)大会上公布的数据显","content":"<html><body><div>\n<div>\n<b>【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】</b>智通财经APP获悉，当地时间6月23日，礼来(LLY.US)在芝加哥举行的美国糖尿病协会(ADA)大会上公布的数据显示，其实验性药物Bimagrumab在与诺和诺德(NVO.US)的GLP-1类减肥药Wegovy(司美格鲁肽)联合使用后，能帮助患者在减重的同时维持肌肉量。研究发现，接受Bimagrumab与Wegovy联合治疗的患者在48周后体重降低22.1%，其中92.8%的体重减少来自身体脂肪。相比之下，仅使用Wegovy的试验患者体重降低15.7%，且71.8%的体重减少来自身体脂肪。这表明，与联用方案相比，单独使用Wegovy的患者会流失更多瘦肌肉量。                </div>\n</div></body></html>","source":"live_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-25 16:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23日，礼来(LLY.US)在芝加哥举行的美国糖尿病协会(ADA)大会上公布的数据显示，其实验性药物Bimagrumab在与诺和诺德(NVO.US)的GLP-1类减肥药Wegovy(司美格鲁肽)联合使用后，能帮助患者在减重的同时维持肌肉量。研究发现，接受Bimagrumab与...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","GLP":"Global Partners Lp","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4144":"石油与天然气的储存和运输","BK4599":"减肥药","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","BK4534":"瑞士信贷持仓","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","NVO":"诺和诺德","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","ADA.AU":"ADACEL TECHNOLOGIES LIMITED","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LLY":"礼来","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD"},"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2546804291","content_text":"【礼来(LLY.US)新药联用Wegovy减重效果佳！大摩唱多：股价有望上涨46%】智通财经APP获悉，当地时间6月23日，礼来(LLY.US)在芝加哥举行的美国糖尿病协会(ADA)大会上公布的数据显示，其实验性药物Bimagrumab在与诺和诺德(NVO.US)的GLP-1类减肥药Wegovy(司美格鲁肽)联合使用后，能帮助患者在减重的同时维持肌肉量。研究发现，接受Bimagrumab与Wegovy联合治疗的患者在48周后体重降低22.1%，其中92.8%的体重减少来自身体脂肪。相比之下，仅使用Wegovy的试验患者体重降低15.7%，且71.8%的体重减少来自身体脂肪。这表明，与联用方案相比，单独使用Wegovy的患者会流失更多瘦肌肉量。","news_type":1,"symbols_score_info":{"ADA.AU":1,"GLP":1,"LLY":1,"NVO":1}},"isVote":1,"tweetType":1,"viewCount":79,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":48,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/449798527656512"}